Literature DB >> 6594184

Reversible hepatotoxicity related to amphotericin B.

M A Miller.   

Abstract

Hepatotoxicity is regarded as a rare side effect of amphotericin B therapy. A patient with acute myelogenous leukemia who had normal liver function was treated with amphotericin B for fungal pneumonia. While he was receiving the drug at high dosages asymptomatic elevation of the levels of alkaline phosphatase, serum glutamic oxaloacetic transaminase, serum glutamic pyruvic transaminase, lactic dehydrogenase and bilirubin was noted. The levels returned to normal when the drug was discontinued. Rechallenge with a lower dosage prompted a rapid rise in the levels, with subsequent return to normal when the medication was withdrawn.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6594184      PMCID: PMC1483710     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  8 in total

1.  NEPHROTOXICITY OF AMPHOTERICIN B; EARLY AND LATE EFFECTS IN 81 PATIENTS.

Authors:  W T BUTLER; J E BENNETT; D W ALLING; P T WERTLAKE; J P UTZ; G J HILL
Journal:  Ann Intern Med       Date:  1964-08       Impact factor: 25.391

2.  ANEMIA INDUCED BY AMPHOTERICIN B.

Authors:  M W BRANDRISS; S M WOLFF; R MOORES; F STOHLMAN
Journal:  JAMA       Date:  1964-08-31       Impact factor: 56.272

3.  Fatal toxic reaction to amphotericin B in cryptococcal meningo-encephalitis.

Authors:  B M CARNECCHIA; J F KURTZKE
Journal:  Ann Intern Med       Date:  1960-11       Impact factor: 25.391

4.  Adverse drug reactions-a matter of opinion.

Authors:  F E Karch; C L Smith; B Kerzner; J M Mazzullo; M Weintraub; L Lasagna
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

Review 5.  Chemotherapy of systemic mycoses (first of two parts).

Authors:  J E Bennett
Journal:  N Engl J Med       Date:  1974-01-03       Impact factor: 91.245

6.  Clinical biostatistics. 28. The biostatistical problems of pharmaceutical surveillance.

Authors:  A R Feinstein
Journal:  Clin Pharmacol Ther       Date:  1974-07       Impact factor: 6.875

Review 7.  Strategies in the treatment of systemic fungal infections.

Authors:  G Medoff; G S Kobayashi
Journal:  N Engl J Med       Date:  1980-01-17       Impact factor: 91.245

8.  Amphotericin B pharmacokinetics in humans.

Authors:  A J Atkinson; J E Bennett
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

  8 in total
  3 in total

1.  Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection.

Authors:  Jiun-Ling Wang; Chia-Hsuin Chang; Yinong Young-Xu; K Arnold Chan
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

2.  Comparison of the effects of liposomal amphotericin B and conventional amphotericin B on propafenone metabolism and hepatic cytochrome P-450 in rats.

Authors:  G Inselmann; A Volkmann; H T Heidemann
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

3.  Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits.

Authors:  J W Lee; M A Amantea; P A Francis; E E Navarro; J Bacher; P A Pizzo; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.